Months after an FDA panel voted against Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug, a second panel reversed the decision in a surprise vote before the agency approved the controversial ALS treatment Sept. 29.
Read the full post on Becker's Hospital Review - Healthcare News
